Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Carboplatin for Recurrent High-grade Glioma
NCT04740190Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of talazoparib in glioma and glioblastoma (GBM), sponsored by The University of Hong Kong. Started Jan 2021; status: completed.
02
Drugs
talazoparib
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT04740190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740190.